Media coverage about XBiotech (NASDAQ:XBIT) has trended somewhat positive on Monday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. XBiotech earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.4801347246835 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
XBiotech (NASDAQ:XBIT) traded down $0.08 during mid-day trading on Monday, hitting $4.14. The stock had a trading volume of 112,100 shares, compared to its average volume of 216,306. XBiotech has a 52 week low of $2.77 and a 52 week high of $20.18.
ILLEGAL ACTIVITY NOTICE: “XBiotech (XBIT) Receives News Impact Score of 0.05” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/04/xbiotech-xbit-receives-news-impact-score-of-0-05.html.
XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.
What are top analysts saying about XBiotech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for XBiotech Inc. and related companies.